Novo Nordisk released its latest earnings and raised its 2026 financial outlook this week, but the market response was not what the company hoped for. The results highlight how much ground Novo Nordisk still needs to make up against Eli Lilly in the weight loss drug market. For readers watching this industry, the numbers show demand keeps growing, even as the two leading companies pull in different directions, and that has real effects on cost and access.
That push to close the gap comes as Eli Lilly continues pulling ahead in the GLP-1 market with drugs like Zepbound and Mounjaro. Wall Street remains skeptical about whether the higher outlook signals a real turnaround for Novo Nordisk's obesity business, given that competition from Eli Lilly keeps intensifying. Novo Nordisk's own Wegovy pill topped 5 million U.S. prescriptions, a sign that demand for its products has not disappeared. Still, the company signaled that sales and profit could decline compared with the previous year, even with the improved outlook. That mixed picture explains why analysts are not fully convinced Novo Nordisk has a clear path back to sustainable growth.
The stock drop caught many investors off guard, given that Novo Nordisk had just delivered improved guidance for 2026. Shares fell more than 6% as investors seemed to focus less on the raised outlook and more on the company's signal that sales and profit could still decline year over year. This reaction suggests that raising guidance alone was not enough to reassure shareholders about the underlying health of the obesity drug business. For readers holding Novo Nordisk stock, the drop is a reminder that market reaction often depends on the details behind a headline number, not just the number itself.
The contrast with Novo Nordisk was stark, as Eli Lilly's raised revenue forecast sent its stock up about 5% in premarket trading. Investors responded to a beat-and-raise quarter in which Mounjaro and Zepbound together drove nearly $23 billion in revenue for the period. Eli Lilly's newly launched obesity pill also made its first contribution to results, adding another growth driver beyond its existing injectable drugs. Analysts have since raised their price targets, arguing the stock still has more room to run given the strength of Eli Lilly's GLP-1 business.
That $250 million figure, disclosed by Bank of America CEO Brian Moynihan, covers GLP-1 medications such as Ozempic, Wegovy, and Zepbound provided to the company's employees. He called the spending a good investment, even though the number illustrates how costly these drugs have become for large employers covering thousands of workers. Bank of America is not alone in facing this pressure, as employers across the country have grappled with rising demand for GLP-1 drugs that can cost thousands of dollars per patient each year. The scale of Bank of America's spending gives a concrete sense of what widespread GLP-1 coverage costs a major employer.
That mutation, found in roughly one in 7,000 people, appears to act like Ozempic in the body without any medication involved. Researchers have described it as a naturally occurring version of what GLP-1 drugs try to achieve through pharmaceutical means. This discovery may give researchers a new line of inquiry into how the body regulates weight and appetite. For now, the finding is an early scientific observation rather than a treatment, but it adds another angle to the broader research around GLP-1 biology.
For readers following the GLP-1 drug market, this week's earnings show that strong demand does not guarantee a strong stock reaction, and it does not close the gap between competitors on its own. If you hold shares in either company, or you rely on these drugs through an employer health plan, it may be worth watching how each company's pipeline and pricing decisions develop into next year. And if you are curious about the science behind these drugs, the discovery of a naturally occurring gene mutation is a reminder that GLP-1 research extends well beyond the medications currently on the market.
Key details
Novo Nordisk raised its 2026 outlook while trying to close the gap with Eli Lilly.
Even after raising its 2026 guidance, Novo Nordisk's stock fell more than 6%.
Eli Lilly raised its annual revenue forecast, sending shares up about 5%.
Bank of America now spends $250 million a year on GLP-1 drugs for employees.
Scientists found a gene mutation, in one of 7,000 people, that acts like Ozempic.
Sources
We're increasing our Eli Lilly price target after another beat-and-raise quarter — CNBC
This GLP-1 stock has bigger opportunities to boost its share price — CNBC
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins — Benzinga
Scientists discover a ‘skinny gene’ mutation that acts like Ozempic — Scientific American
Tim McGraw's daughter says Ozempic revived eating disorder — Mechanicsburg Patriot News
Tim McGraw's daughter says Ozempic revived eating disorder — Staten Island Advance
Tim McGraw's daughter says Ozempic revived eating disorder — M Live Michigan
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case — Reuters
"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand — ZeroHedge
Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong — Reuters
Novo Nordisk's raised forecast fails to change the debate over its obesity business — CNBC
Gracie McGraw Says Ozempic Brought Back Her Eating Disorder — kdhlradio.com
Gracie McGraw Says Ozempic Brought Back Her Eating Disorder — Taste of Country
Calls to poison centers skyrocket amid rise in use of GLP-1 drugs — NBC 5 Chicago
Who qualifies for the new obesity drug — The Dallas Morning News
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks — Benzinga
Novo Nordisk's Q2 profit beats forecasts, raises outlook — Reuters
GLP-1 Isn't Just About Weight Loss-REX's New ETF Proves It — Benzinga